These medications include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management), liraglutide (Victoza for diabetes and Saxenda for weight management), dulaglutide (Trulicity for diabetes), and tirzepatide (Mounjaro for diabetes), which combines GLP-1 action with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism
Biochem Pharmacol 39:5965 Schnleben-Janas A, Kirsch P, Mittl PR, Schirmer RH, Krauth-Siegel RL (1996) Inhibition of human glutathione reductase by 10-arylisoalloxazines: crystalline, kinetic, and electrochemical studies
The neurochemical effects of GLP-1 medications on reward pathways appear to be dose-dependent and reversible
Participants using Zepbound (tirzepatide) achieved an average weight loss of 20.2% compared to 13.7% with Wegovy (semaglutide), translating to 50.3 pounds versus 33.1 pounds of weight reduction respectively ^2
Many patients now ask us about these drugs effects on mental health, particularly anxiety
However, none have yet been approved for the treatment of NASH, while many others have already been deemed ineffective (e.g., elafibranor, seladelpar, emricasan, selonsertib and elobixibat)